Ryze Superfoods, a direct-to-consumer brand that built a substantial social media following around its mushroom-infused coffee blend, received a warning letter from the Federal Trade Commission citing health and wellness claims in its advertising that the agency said were not backed by competent and reliable scientific evidence.DOCUMENTED
The company's products — marketed under the Ryze Mushroom Coffee brand — were promoted across digital channels with claims touching on immunity support, cognitive performance, gut health, and stress reduction. The FTC's warning indicated that claims of this nature, made in a commercial context, require a level of scientific substantiation that the company's marketing did not appear to meet.
- Ryze Superfoods received an FTC warning letter over health claims in its mushroom coffee marketing.
- Claims included references to immunity, focus, gut health, and stress response benefits.
- FTC requires competent and reliable scientific evidence to support health and wellness marketing claims.
- Mushroom supplements have grown rapidly as a product category, with limited clinical evidence for most specific claims.
- The warning letter does not by itself impose a financial penalty but signals potential enforcement if practices continue.
What Ryze Was Selling and What It Said
Ryze Superfoods entered the functional beverage space with a product combining ground coffee with a blend of mushroom extracts — commonly including varieties such as lion's mane, cordyceps, chaga, turkey tail, and reishi. These ingredients have a history of use in traditional medicine in various cultures, and some have been the subject of preliminary scientific research. The company's marketing drew on that research tradition liberally, using language suggesting that drinking Ryze Mushroom Coffee would produce specific, measurable health outcomes.REVIEWED
Advertising for the product appeared across the company's website, email campaigns, and social media platforms, including Instagram, TikTok, and YouTube. Promotional language described the product as supporting focus, immunity, gut microbiome health, and the body's response to stress — benefits the company tied to the functional properties of its mushroom blend. Influencer partnerships amplified these claims to audiences numbering in the millions.REVIEWED
The FTC's Substantiation Standard
The FTC's enforcement framework for health claims in advertising requires that a marketer possess, before making a claim, evidence that is competent and reliable — meaning well-controlled human clinical studies, where the product being tested is the product being sold, at dosages consistent with actual use. Preliminary animal studies, in-vitro research, or the fact that an ingredient has a history of traditional use are not considered adequate substantiation for specific health benefit claims made in commercial advertising.DOCUMENTED
This standard applies to supplement and food product advertising broadly, and the FTC has increasingly applied it to the functional food and adaptogen space as brands in that category have scaled rapidly through social media. The challenge for many mushroom extract brands is that while some individual mushroom compounds have been studied in research settings, the studies are often small, conducted on extracts rather than finished consumer products, or focused on populations or conditions different from the broad wellness market the brands are targeting.REVIEWED
A long history in traditional medicine is not the same as a clinical trial. Regulators apply the latter standard, not the former, when a company sells health outcomes to consumers.
The Broader Mushroom Coffee Market
Ryze Superfoods was not alone in making the kinds of claims the FTC flagged. The functional coffee and mushroom supplement category grew substantially in the years following the pandemic, driven by consumer interest in immunity, cognitive health, and alternatives to traditional caffeine products. Dozens of brands entered the space, and many adopted similar marketing frameworks emphasizing the same cluster of benefits — immunity, focus, energy, gut health, stress — with varying degrees of scientific support cited in their materials.REVIEWED
The FTC warning to Ryze was part of a broader pattern of agency scrutiny applied to this product category. Companies that had built large audiences through persuasive wellness marketing were put on notice that the standard for advertising in a commercial context is materially higher than what is permissible in, for example, educational or journalistic discussion of the same ingredients. The agency has consistently maintained that a company cannot draft its advertising from research summaries and then treat those summaries as the substantiation for the marketing claims.
Warning Letters and What Comes Next
An FTC warning letter is not a finding of violation, and it does not impose any immediate financial penalty on the recipient. It is, however, a formal notice that the agency has reviewed the company's marketing and believes it may not meet the substantiation standard, and that if the company does not modify its advertising, further enforcement action — including a complaint, a consent order, and civil monetary penalties — is possible. Companies that receive warning letters and continue the flagged practices without modification significantly increase their exposure in any subsequent enforcement proceeding, because the warning removes any argument that the company lacked notice of the FTC's concern.DOCUMENTED
For Ryze Superfoods specifically, the letter would have required the company to review its advertising across all channels, assess whether any specific health claims it was making were supported by the required level of evidence, and modify or remove claims that did not meet that standard. The company's response to the letter — whether it modified its marketing, sought additional scientific evidence to substantiate remaining claims, or continued practices the FTC had flagged — was not made public through any subsequent consent order in the period following the warning.
What Consumers Should Know
The FTC's action against Ryze Superfoods illustrates a recurring gap in the functional food and supplement marketplace. Products in this category are not approved by the Food and Drug Administration before they go on sale, and the FDA's oversight of supplement marketing is largely complaint-driven rather than pre-market. The result is a marketplace where health benefit claims routinely outpace the evidence behind them, and where consumers may purchase products expecting outcomes that the clinical literature does not reliably support at the doses and formulations actually sold.REVIEWED
Mushroom extract products specifically occupy an unusual position: the underlying research on individual compounds like beta-glucans in certain fungi is genuine and ongoing, and some findings are promising. But the distance between a promising laboratory result and a proven consumer health benefit is substantial, and brands that collapse that distance in their advertising are making claims that the regulatory framework does not permit them to make. Consumers evaluating these products should look for whether specific claims point to clinical evidence involving the actual finished product rather than citing ingredient-level research that may not translate to the product as sold and consumed.
Sources behind this report
Have documents relevant to this story? Reach us through our tips channel.